Comprehensive Analysis of The Significance of Hypoxia-Related Genes in Ovarian Cancer

Wancheng Zhao

Shengjing Hospital of China Medical University

Lili Yin (✉ llyin@cmu.edu.cn)

Shengjing Hospital of China Medical University

Research Article

Keywords: ovarian cancer, hypoxia-related gene, immune infiltrate, consensus clustering, PCA algorithm

Posted Date: May 18th, 2021

DOI: <https://doi.org/10.21203/rs.3.rs-457769/v2>

License: This work is licensed under a Creative Commons Attribution 4.0 International License.

[Read Full License](#)

Abstract

Background: Hypoxia-related genes have been reported to play important roles in a variety of cancers. However, their roles in ovarian cancer (OC) have remained unknown. Our aim was to explore the significance of hypoxia-related genes in OC patients.

Methods: In this study, 15 hypoxia-related genes were screened from The Cancer Genome Atlas (TCGA) database to group the ovarian cancer patients using the consensus clustering method. Principal component analysis (PCA) was used to calculate the hypoxia score to quantify the hypoxic status.

Results: The OC patients were divided into two hypoxia statuses based on the expression level of the 15 hypoxia-related genes. Most hypoxia-related genes were more highly expressed in the cluster.A group. We also found that patients in the cluster.A group exhibited higher expression level of immune checkpoint-related genes, epithelial-mesenchymal transition-related genes, and immune activation-related genes, as well as elevated immune infiltrates. PCA algorithm indicated that the cluster.A group had higher hypoxia scores.

Conclusions: In summary, our research elucidated the vital role of hypoxia-related genes in immune infiltrates of OC. Our investigation of hypoxic status may be able to improve the efficacy of immunotherapy for OC.

1. Introduction

Ovarian cancer (OC) is one of the most serious threats to female health. Currently, surgery combined with chemotherapy is the main treatment strategy. However, 70% of patients relapse within 3 years [1, 2]. Therefore, it is important to explore new therapeutic strategies to improve clinical efficacy and delay recurrence. Immune checkpoint inhibitors (ICI) targeting programmed death protein 1 (PD1), programmed death ligand (PD-L1), and cytotoxic T lymphocyte-associated protein 4 (CTLA-4) have been approved for the treatment of a variety of malignancies. Although PD-L1 is highly expressed in epithelial ovarian cancer (EOC), ICI monotherapy for PD-1/PD-L1 or CTLA-4 has only shown a response rate of 5.9–15% [3]. Therefore, the search for predictive biomarkers is crucial to improve the effectiveness of ICI treatment.

The progression and metastasis of tumors mainly depend on the bidirectional interaction between tumor cells and their microenvironment. The tumor microenvironment (TME) includes immune cells, fibroblasts, endothelial cells, mesenchymal stem cells, extracellular matrix, blood vessels, and cytokines. Hypoxia is closely related to the TME [4]. The limitation of oxygen diffusion and the disordered vascular system prevent rapidly developing tumors from obtaining sufficient oxygen, resulting in a hypoxic microenvironment [5, 6]. Increasing studies have reported that hypoxia was related to the progression of cancers [7–9]. For example, Klemba et al. summarized that hypoxia is strongly associated with angiogenesis, chemoresistance, epithelial-to-mesenchymal transition (EMT), prognosis, acquisition of stem-like characters, and immune suppression of ovarian cancer [10]. However, the studies about the role of hypoxia in the progression and immune infiltrates of OC was less.

In this study, we comprehensive analysis of the functions of 15 hypoxia-related genes in the progression and immune infiltrates of OC based on TCGA-OV dataset. The patients in TCGA-OV dataset were divided into two hypoxia statuses using the consensus clustering method. We found that patients in the cluster.A group exhibited elevated immune infiltrates, suggesting that they may be more sensitive to ICI treatment.

2. Materials And Methods

2.1 Data acquisition

Mutation data, RNA transcriptome profiles, and corresponding clinical data of OC were obtained from TCGA database (<https://portal.gdc.cancer.gov/>). TCGA-OV dataset contains data on 379 patients with OC. The histological subtype of the OC patients was serous cystadenocarcinoma. The corresponding clinical data included stage, grade, survival state, and overall survival. The vast majority of OC patients were in stage III or IV, with a G3 grade. Fifteen hypoxia-related genes extracted from the dataset.

2.2 Consensus clustering of distinct hypoxic statuses based on 15 hypoxia-related genes

Consensus clustering is an algorithm used to identify different subgroups based on resampling. The “ConsensusClusterPlus” package in R was used to divide the OC patients into distinct hypoxic statuses based on the 15 hypoxia-related genes using consensus clustering and the consensus clustering was repeated 1000 times [11].

2.3 Identification of differentially expressed genes (DEGs) between distinct hypoxic statuses

We screened the DEGs between the distinct hypoxic statuses based on the RNA transcriptome profiles from TCGA-OV dataset using the “limma” package. P-value < 0.01 and logFC > 1 were selected as the screening criteria.

2.4 Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) functional enrichment analyses

GO and KEGG enrichment analyses were applied to identify the possible mechanisms and pathways by which the DEGs are involved in the hypoxic status of OC through the “clusterProfiler” package.

2.5 PCA to quantify the hypoxic status

PCA is a linear dimensionality reduction method proposed by the famous statistician Karl Pearson in 1901 [12]. The PCA algorithm maps high-dimensional data to low-dimensional space and retains some features of the original data. We used PCA to calculate the hypoxia score for each patient from TCGA-OV dataset. Then, the hypoxia score was calculated by the following formula: hypoxia score = $\sum (PC1_i + PC2_i)$, where PC1 represents principal component 1, PC2 represents principal component 2, and i

represents the expression levels of the 15 hypoxia-related genes in samples from TCGA-OV dataset [13, 14].

2.6 Single sample gene set enrichment analysis (ssGSEA)

ssGSEA was performed to calculate the abundance of 28 immune cell types in samples from TCGA-OV dataset. First, we obtained the genes representative of each immune cell type. These genes were obtained from the study by Charoentong et al., in which various human immune cell subtypes were stored [15]. Next, we select the genes in the transcriptome profiles. The enrichment scores calculated by ssGSEA analysis were used to represent the relative abundance of the 28 immune cell types in each sample.

2.7 Statistical analysis

Kruskal–Wallis tests were used to evaluate the difference in different hypoxic statuses. The Kaplan-Meier curve and log-rank method were used to compare the survival outcome between different hypoxic statuses. The “maftools” package in R software was used to screen genes that were differentially mutated between different hypoxic statuses. The results were visualized with forest plots and co-oncoplots. All statistical analyses were performed using R version 4.0.0.

3. Results

3.1 Two distinct hypoxic statuses identified by consensus clustering

We performed clustering of the consensus matrix to obtain two matrices, 0 and 1, where 1 represents clustering together and 0 represents complete separation. As shown in Fig. 1A, we found that similar samples were all clustered together in the blue module. However, there was substantial noise in the blue module shown in Fig. 1B–D. Therefore, we believed that the clustering effect was optimal at $k = 2$, so we divided the ovarian cancer samples into two groups (cluster.A and cluster.B). The cluster.A group contained 192 patients, while the cluster.B group contained 187. Then, we illustrated the levels of differential expression of the 15 hypoxia-related genes between these two clusters using a histogram. With the exception of MRPS17, the other 14 hypoxia-related genes showed higher expression levels in the cluster.A group (Fig. 1E). PCA indicated that the 15 hypoxia-related genes could divide the two hypoxic statuses (Fig. 1F).

Differential analysis indicated that patients in the cluster.A group had increased immune cell infiltration (Fig. 1G). The Kaplan-Meier curve showed that there was no significant difference in survival outcome between the cluster.A group and the cluster.B group (Fig. 1H). Figure 2A shows that the immune checkpoint-related genes CD274, CD80, CD86, HAVCR2, IDO1, PDCD1LG2, and VTCN1 were higher expressed in the cluster.A group (Fig. 2A). Moreover, the immune activation-related genes CXCL10, CXCL9, GZMB, PRF1, and TNF had higher expression levels in the cluster.A group (Fig. 2B). Hypoxia can also induce epithelial-mesenchymal transition (EMT) of cancers [16]. In our research, we confirmed that the

EMT-related genes COL4A1, PDGFRA, TGFBR2, TWIST1, VIM, and ZEB1 were higher expressed in the cluster.A group (Fig. 2C).

3.2 GO and KEGG enrichment analyses

A total of 227 hypoxia-related DEGs between the two hypoxic statuses were selected. To understand the possible enriched functions and pathways of these DEGs in OC, GO and KEGG functional enrichment analyses were performed. The GO functional enrichment analysis indicated that the genes were mainly enriched in GO:0006954 ~ inflammatory response, GO:0071347 ~ cellular response to interleukin-1, GO:0006955 ~ immune response, GO:0005125 ~ cytokine activity, and GO:0071356 ~ cellular response to tumor necrosis factor, all of which are related to inflammatory and immune responses (Fig. 3A). Moreover, the KEGG functional enrichment analysis indicated that the genes were mainly enriched in cytokine-cytokine receptor interaction, ECM-receptor interaction, NOD-like receptor signaling pathway, Jak-STAT signaling pathway, MAPK signaling pathway, and Rap1 signaling pathway (Fig. 3B).

3.3 Identification of two distinct hypoxia gene statuses

Consensus clustering was performed to based on the 227 hypoxia-related DEGs to further confirm the validity of the initial analysis. Two distinct gene clusters was obtained (gene cluster.A and gene cluster.B) (Fig. 4A–D). Figure 3E indicates that the expression levels of most of the 15 hypoxia-related genes were higher in gene cluster.A than in gene cluster.B (Fig. 4E). PCA indicated that the 227 hypoxia-related DEGs could completely distinguish the two gene clusters (Fig. 4F). Figure 4G shows that all of the other 27 of 28 immune cell types were more highly infiltrated in the gene cluster.A group, with the exception of CD56bright natural killer cells. Moreover, the Kaplan-Meier curve indicated that the survival outcome did not differ significantly between the two gene clusters (Fig. 4H). The expression levels of immune checkpoint-related genes CD274, CD80, CD86, HAVCR2, IDO1, PDCD1, PDCD1LG2, TNFRSF8, and VTCN1 were higher in the gene cluster.A group (Fig. 5A). With the exception of TBX2, all immune activation-related genes CD8A, CXCL10, CXCL9, GZMA, GZMB, IFNG, PRF1, and TNF were overexpressed in the cluster.A group (Fig. 5B). The EMT-related genes COL4A1, PDGFRA, TGFBR2, TWIST1, VIM, and ZEB1 were more highly expressed in the gene cluster.A group (Fig. 5C).

3.4 PCA algorithm to quantify the hypoxic status

To quantify the hypoxic status, each patient was assigned a hypoxia score using a PCA algorithm. Most of the 15 hypoxia-related genes were higher expressed in the high-score group (Fig. 6A). PCA indicated that the 227 hypoxia-related DEGs could divide the two score groups (Fig. 6B). We compared the hypoxia score between the clusters identified using either the 15 hypoxia-related genes or the 227 hypoxia-related DEGs. The hypoxia score in cluster.A or gene cluster.A was higher than that in cluster.B or gene cluster.B (Fig. 6C and D). However, the hypoxia score showed no statistically significant difference among the different stages and grades (Fig. 6E and F). The relationship among hypoxic status, hypoxia gene status, and hypoxia score was visualized in a Sankey diagram (Fig. 6G). 28 immune cell types were highly infiltrated in the high-score group (Fig. 6H). The K-M curve indicated that the survival outcome have no differ, which was in line with our expectations (Fig. 6I). Roughly similar to previous results, the expression

levels of immune checkpoint-related genes (Fig. 7A), immune activation-related genes (Fig. 7B), and EMT-related genes (Fig. 7C) were higher in the high-score group. Finally, considering that heterologous proteins produced by gene mutations can lead to an increase of immune cell infiltration, we analyzed the different gene mutations between the high- and low-score groups with different immune infiltrate statuses using the “maftools” package, and visualized by forest plots (Fig. 8A) and co-oncoplots (Fig. 8B). The results indicated that the mutation frequencies of BRCA1, PRUNE2, APOB, RELN, MDN1, ZSWIM8, MGAT4C, FAT2, and VWF were higher in the high-score group, while those of HECW1 and RB1 were on the contrary.

4. Discussion

Studies showed that hypoxia-related genes are associated with the malignant progression of ovarian cancer [17–19]. However, most of the research focused on exploring the function of single hypoxia-related genes in OC. There have been fewer reports investigating the significance of hypoxia-related signature sets in OC. In this study, we extracted the RNA transcriptome profiles of 15 hypoxia-related genes from TCGA-OV dataset. Then, we classified the 379 OC patients into two groups using the consensus clustering method. We explored significant differences in immune infiltration level between the groups. Notably, previous studies also identified the relationship between hypoxia and immune infiltrates in cancer. For example, Wang et al. revealed that hypoxia can aggravate immune cell infiltration to promote the development of hepatocellular carcinoma (HCC) by inducing myeloid derived growth factor (MYDGF) [20]. Moreover, Xiao et al. established a four-gene tumor microenvironment-related model based on TCGA-GBM dataset. These four genes were reported to potentially be associated with the hypoxic phenotype of glioblastoma [21]. Furthermore, Gong et al. divided the breast cancer patients from TCGA database into two groups based on the expression of 13 hypoxia-related genes. The results indicated that the immune infiltrating state differed between cluster1 and cluster2, suggesting the hypoxia can regulate immune infiltrates in breast cancer [22]. Our study further supports the relationship between hypoxia and immune infiltrates in OC, but the potential mechanism behind this should be investigated. We hypothesized that patients in the cluster.A group were more sensitive to immunotherapy, given their higher level of immunoinfiltration. EMT is a biological process in which epithelial cells transform into mesenchymal ones through specific processes. Previous studies reported that hypoxia was involved in the specific processes of EMT [23–25]. Our research also supported that the cluster.A group with an activated hypoxic status showed higher expression levels of EMT-related genes.

Moreover, GO and KEGG analyses based on the 227 hypoxia-related DEGs further confirmed that hypoxia was associated with inflammatory response, immune response, and EMT of OC. To quantify the hypoxic state of patients and facilitate clinical interpretation, a PCA algorithm was used to calculate a hypoxia score for each patient. A high hypoxia score was associated with activated immune infiltrates, and the upregulation of immune checkpoint-related genes, EMT-related genes, and immune activation-related genes, suggesting that the hypoxia score calculated by the PCA algorithm can well quantify the hypoxic state of OC patients. All of the above results repeatedly indicate the important role of hypoxia in the immune infiltration and malignant progression of OC. The mutual validation of the analysis results led us

to believe that the hypoxia score constructed based on the hypoxia-related genes would be beneficial for the clinical selection of patients sensitive to immune checkpoint inhibitors.

Cell mutations can be divided into germline mutations and somatic mutations. The former are found in all cells in the body, due to originally occurring in the sperm or egg of the individual's parent. In contrast, somatic mutations are acquired mutations limited to a certain part of the body, which can occur due to environmental factors [26]. Non-synonymous somatic mutations of tumors may produce immune-stimulating neoantigens [27, 28]. Therefore, we hypothesize that hypoxia can elicit an immune response by inducing mutations in specific genes that produce neoantigens. To explore the differentially gene mutated between the two hypoxia score- group, the “maftools” package was used. The mutation frequencies of BRCA1, PRUNE2, APOB, RELN, MDN1, ZSWIM8, MGAT4C, FAT2, and VWF were higher in the group with a high hypoxia score. From a search of the literature, no relevant research on hypoxia-regulating gene mutations of OC has been reported. Our results may provide a reference for future research in this field. Nevertheless, the potential immunogenicity of BRCA1 mutation has been demonstrated, so it may act as a biomarker for ICI therapies of patients with high grade serous ovarian cancer [29]. This provides some support for the reliability of our study.

5. Conclusions

In conclusion, the current study revealed that 15 hypoxia-related genes were related to the immune infiltrates and malignant progression of OC. Although the specific regulatory mechanism is still unknown, it is clear that these 15 hypoxia-related genes can play a vital role in guiding ICI therapy of OC.

Abbreviations

OC: ovarian cancer; TCGA: The Cancer Genome Atlas; PCA: principal component analysis; PFS: progression-free survival; ICI: Immune checkpoint inhibitors; PD1: programmed death protein 1; PD-L1: programmed death ligand; CTLA-4: cytotoxic T lymphocyte-associated protein 4; EOC: epithelial ovarian cancer; TME: tumor microenvironment; EMT: epithelial-to-mesenchymal transition; DEGs: differentially expressed genes; GO: Gene Ontology; KEGG: Kyoto Encyclopedia of Genes and Genomes; ssGSEA: single sample gene set enrichment analysis; HCC: hepatocellular carcinoma; MYDGF: myeloid derived growth factor.

Declarations

Ethical Approval and Consent to participate

Not applicable.

Consent for publication

Not applicable.

Availability of supporting data

All data generated or analyzed during this study are included in this published article and its supplementary information files.

Competing interests

The authors declare that they have no competing interests.

Funding

Not applicable.

Author Contributions

Wancheng Zhao and Lili Yin conceived and designed the study, developed the methodology, analyzed and interpreted the data, and wrote, reviewed, and/or revised the manuscript.

Acknowledgments

The authors thank the researchers who provided TCGA public datasets.

Authors' information

Wancheng Zhao: 373986045@qq.com.

Lili Yin: llyin@cmu.edu.cn.

References

1. Ledermann JA, Raja FA, Fotopoulou C, Gonzalez-Martin A, Colombo N, Sessa C. Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Annals of oncology: official journal of the European Society for Medical Oncology*. 2018;29(Suppl 4):iv259.
2. Chen Y, Bi F, An Y, Yang Q. Identification of pathological grade and prognosis-associated lncRNA for ovarian cancer. *Journal of cellular biochemistry*. 2019;120(9):14444–54.
3. Hamanishi J, Mandai M, Ikeda T, Minami M, Kawaguchi A, Murayama T, Kanai M, Mori Y, Matsumoto S, Chikuma S, Matsumura N, Abiko K, Baba T, et al. Safety and Antitumor Activity of Anti-PD-1 Antibody, Nivolumab, in Patients With Platinum-Resistant Ovarian Cancer. *Journal of clinical oncology: official journal of the American Society of Clinical Oncology*. 2015;33(34):4015–22.
4. Meng W, Hao Y, He C, Li L, Zhu G. Exosome-orchestrated hypoxic tumor microenvironment. *Mol Cancer*. 2019;18(1):57.

5. Chen PS, Chiu WT, Hsu PL, Lin SC, Peng IC, Wang CY, Tsai SJ. Pathophysiological implications of hypoxia in human diseases. *Journal of biomedical science*. 2020;27(1):63.
6. Abou Khouzam R, Goutham HV, Zaarour RF, Chamseddine AN, Francis A, Buart S, Terry S, Chouaib S. Integrating tumor hypoxic stress in novel and more adaptable strategies for cancer immunotherapy. *Sem Cancer Biol*. 2020;65:140–54.
7. Farina AR, Cappabianca L, Sebastiano M, Zelli V, Guadagni S, Mackay AR. Hypoxia-induced alternative splicing: the 11th Hallmark of Cancer. *Journal of experimental clinical cancer research: CR*. 2020;39(1):110.
8. Mo Z, Yu L, Cao Z, Hu H, Luo S, Zhang S. Identification of a Hypoxia-Associated Signature for Lung Adenocarcinoma. *Frontiers in genetics*. 2020;11:647.
9. Jing X, Yang F, Shao C, Wei K, Xie M, Shen H, Shu Y. Role of hypoxia in cancer therapy by regulating the tumor microenvironment. *Mol Cancer*. 2019;18(1):157.
10. Klemba A, Bodnar L, Was H, Brodaczewska KK, Wcislo G, Szczylik CA, Kieda C Hypoxia-Mediated Decrease of Ovarian Cancer Cells Reaction to Treatment: Significance for Chemo- and Immunotherapies. *International journal of molecular sciences*. 2020; 21(24).
11. Wilkerson MD, Hayes DN. ConsensusClusterPlus: a class discovery tool with confidence assessments and item tracking. *Bioinformatics*. 2010;26(12):1572–3.
12. LIII, LIII and LIII. On lines and planes of closest fit to systems of points in space. London: Edinburgh & Dublin Philosophical Magazine & Journal of Science; 1901.
13. Zeng D, Li M, Zhou R, Zhang J, Sun H, Shi M, Bin J, Liao Y, Rao J, Liao W. Tumor Microenvironment Characterization in Gastric Cancer Identifies Prognostic and Immunotherapeutically Relevant Gene Signatures. *Cancer Immunol Res*. 2019;7(5):737–50.
14. Zhang B, Wu Q, Li B, Wang D, Wang L, Zhou. YL. m(6)A regulator-mediated methylation modification patterns and tumor microenvironment infiltration characterization in gastric cancer. *Mol Cancer*. 2020;19(1):53.
15. Charoentong P, Finotello F, Angelova M, Mayer C, Efremova M, Rieder D, Hackl H, Trajanoski Z. Pan-cancer Immunogenomic Analyses Reveal Genotype-Immunophenotype Relationships and Predictors of Response to Checkpoint Blockade. *Cell Rep*. 2017;18(1):248–62.
16. Zhang Q, Huang R, Hu H, Yu L, Tang Q, Tao Y, Liu Z, Li J, Wang G. Integrative Analysis of Hypoxia-Associated Signature in Pan-Cancer. *iScience*. 2020;23(9):101460.
17. Zhang Y, Xu Y, Ma J, Pang X, Dong M. Adrenomedullin promotes angiogenesis in epithelial ovarian cancer through upregulating hypoxia-inducible factor-1 α and vascular endothelial growth factor. *Scientific reports*. 2017;7:40524.
18. Santana-Rivera Y, Rabelo-Fernández RJ, Quiñones-Díaz BI, Grafals-Ruiz N, Santiago-Sánchez G, Lozada-Delgado EL, Echevarría-Vargas IM, Apiz J, Soto D, Rosado A, Meléndez L, Valiyeva F, Vivas-Mejía PE. Reduced expression of enolase-1 correlates with high intracellular glucose levels and increased senescence in cisplatin-resistant ovarian cancer cells. *American journal of translational research*. 2020;12(4):1275–92.

19. Xintaropoulou C, Ward C, Wise A, Queckborner S, Turnbull A, Michie CO, Williams ARW, Rye T, Gourley C, Langdon SP. Expression of glycolytic enzymes in ovarian cancers and evaluation of the glycolytic pathway as a strategy for ovarian cancer treatment. *BMC Cancer*. 2018;18(1):636.
20. Wang X, Mao J, Zhou T, Chen X, Tu H, Ma J, Li Y, Ding Y, Yang Y, Wu H, Tang X. Hypoxia-induced myeloid derived growth factor promotes hepatocellular carcinoma progression through remodeling tumor microenvironment. *Theranostics*. 2021;11(1):209–21.
21. Xiao K, Tan J, Yuan J, Peng G, Long W, Su J, Xiao Y, Xiao Q, Wu C, Qin C, Hu L, Liu K, Liu S, et al. Prognostic value and immune cell infiltration of hypoxic phenotype-related gene signatures in glioblastoma microenvironment. *J Cell Mol Med*. 2020;24(22):13235–47.
22. Gong PJ, Shao YC, Huang SR, Zeng YF, Yuan XN, Xu JJ, Yin WN, Wei L, Zhang JW. Hypoxia-Associated Prognostic Markers and Competing Endogenous RNA Co-Expression Networks in Breast Cancer. *Frontiers in oncology*. 2020;10:579868.
23. Nurwidya F, Takahashi F, Kobayashi I, Murakami A, Kato M, Minakata K, Nara T, Hashimoto M, Yagishita S, Baskoro H, Hidayat M, Shimada N, Takahashi K. Treatment with insulin-like growth factor 1 receptor inhibitor reverses hypoxia-induced epithelial-mesenchymal transition in non-small cell lung cancer. *Biochem Biophys Res Commun*. 2014;455(3–4):332–8.
24. Sun LL, Chen CM, Zhang J, Wang J, Yang CZ, Lin LZ. Glucose-Regulated Protein 78 Signaling Regulates Hypoxia-Induced Epithelial-Mesenchymal Transition in A549 Cells. *Frontiers in oncology*. 2019;9:137.
25. Ruan J, Zhang L, Yan L, Liu Y, Yue Z, Chen L, Wang AY, Chen W, Zheng S, Wang S, Lu Y. Inhibition of hypoxia-induced epithelial mesenchymal transition by luteolin in non-small cell lung cancer cells. *Mol Med Rep*. 2012;6(1):232–8.
26. Perduca V, Alexandrov LB, Kelly-Irving M, Delpierre C, Omichessan H, Little MP, Vineis P, Severi G. Stem cell replication, somatic mutations and role of randomness in the development of cancer. *Eur J Epidemiol*. 2019;34(5):439–45.
27. McGranahan N, Furness AJ, Rosenthal R, Ramskov S, Lyngaa R, Saini SK, Jamal-Hanjani M, Wilson GA, Birkbak NJ, Hiley CT, Watkins TB, Shafi S, Murugaesu N, et al. Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade. *Science (New York)*. 2016; 351(6280):pp. 1463–9.
28. Chen DS, Mellman I. Elements of cancer immunity and the cancer-immune set point. *Nature*. 2017;541(7637):321–30.
29. Dai Y, Sun C, Feng Y, Jia Q, Zhu B. Potent immunogenicity in BRCA1-mutated patients with high-grade serous ovarian carcinoma. *J Cell Mol Med*. 2018;22(8):3979–86.

Figures

Figure 1

Consensus clustering of the 15 hypoxia-related genes in TCGA-OV dataset. (A–D) Consensus matrices of the 15 hypoxia-related genes for $k=2$ –5. (E) Differential expression of the 15 hypoxia-related genes between two clusters. (F) PCA based on the expression of the 15 hypoxia-related genes. (G) Differential immune cell infiltration between two clusters. (H) The Kaplan-Meier curve showed the survival outcome in two clusters. (* $P < 0.05$, ** $P < 0.01$, *** $P < 0.001$, "ns" means no significant difference).

Figure 2

Phenotypes associated with hypoxic status in ovarian cancer. (A) Differential expression of immune checkpoint molecules between cluster.A and cluster.B. (B) Differential expression of immune activation-related genes. (C) Differential expression of epithelial-mesenchymal transition (EMT)-related genes.

Figure 3

Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) functional enrichment analyses. (A) GO functional enrichment analysis visualized with an enrichment circle diagram. (B) KEGG functional enrichment analysis visualized with a bubble diagram. “Rich factor” represents “number of selected genes/number of genes.”

Figure 4

Consensus clustering of the 227 hypoxia-related DEGs in TCGA-OV dataset. (A–D) Consensus matrices of the 227 hypoxia-related DEGs for k=2–5. (E) Differential expression of the 15 hypoxia-related genes between two gene clusters. (F) PCA based on the expression of the 227 hypoxia-related DEGs between the two gene statuses. (G) Differential immune cell infiltration between two gene clusters. (H) The K-M curve showed the survival outcome in two gene clusters.

Figure 5

Phenotypes associated with hypoxia gene status in ovarian cancer. (A) Differential expression of immune checkpoint molecules between two gene clusters. (B) Differential expression of immune activation-related genes between two gene clusters. (C) Differential expression of epithelial-mesenchymal transition (EMT)-related genes between two gene clusters.

Figure 6

Significance of the hypoxia score in ovarian cancer. (A) Differential expression of the 15 hypoxia-related genes between two-score groups. (B) PCA based on the expression of the 227 hypoxia-related DEGs between two-score groups. (C) Differences in hypoxia score between two clusters. (D) Differences in m6A score between two gene.clusters. (E) Differences in hypoxia score between different stages of ovarian cancer. (F) Differences in hypoxia score between tumor grades G1/2 and G3/4. (G) Sankey diagram

revealing the relationship among hypoxic status, hypoxia gene status, and hypoxia score. (H) Differential immune cell infiltration between between two-score groups. (I) The K-M curve showed that the survival outcome between two-score groups.

Figure 7

Phenotypes associated with hypoxia score in ovarian cancer. (A) Differential expression of immune checkpoint molecules between two-score groups. (B) Differential expression of immune activation-related

genes between two-score groups. (C) Differential expression of EMT-related genes between two-score groups.

Figure 8

Differences in genetic mutations between two-score groups. (A) Forest plots showing the genes differentially mutated between two-score groups. (B) Co-oncoplots showing the genes differentially mutated between two-score groups.